Studies of outlier gene expression can give insight into contemporary drivers, and has considerable precedence in prostate cancer (for example, discovery of ETS fusions and SPINK1 subtype [42]), but the high dynamic range and absolute quantification afforded by transcriptome sequencing offers new opportunities not available to previous microarray-based approaches. This evidence concerns the gene SPINK1 and prostate carcinoma.